Welcome to our dedicated page for Becton, Dickinson and Co. news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton, Dickinson and Co. stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology firm committed to advancing healthcare through the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Established in 1897, BD's mission is to enhance medical discovery, diagnostics, and care delivery. The company's extensive product portfolio serves healthcare institutions, physicians, life science researchers, and others across the globe.
BD is noted for being the world’s largest manufacturer and distributor of medical surgical products such as needles, syringes, and sharps-disposal units. The company also excels in producing pre-filled devices, diagnostic instruments, and reagents. Furthermore, BD offers sophisticated flow cytometry and cell-imaging systems. BD Medical represents nearly half of the company's total business, while BD Life Sciences and BD Interventional contribute 27% and 24% of the 2023 revenue, respectively. Impressively, international revenue accounts for 43% of the company's business.
Recent achievements and projects underscore BD's commitment to innovation and sustainability. The company recently collaborated with health care institutions in Denmark to explore recycling used blood collection tubes, achieving significant environmental advancements without compromising safety or quality.
In a pivotal development, BD announced the global commercial release of new cell sorters, enabling researchers in fields such as cell biology, cancer research, and immunology to gain new insights. The BD FACSDiscover™ S8 Cell Sorters incorporate groundbreaking technologies like BD CellView™ Image Technology and BD SpectralFX™ Technology, significantly enhancing real-time imaging and spectral flow cytometry.
BD also reported robust financial performance for the second quarter of fiscal 2024, highlighting strong operating margins and cash flow. This success led to an optimistic outlook and an increased earnings guidance, demonstrating the company’s resilience and strategic execution.
Further solidifying its market position, BD is set to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion. This acquisition expands BD’s portfolio in smart connected care solutions, leveraging advanced AI algorithms for better patient outcomes and adding significant value to its operations.
With a presence in almost every country and a workforce of over 70,000 employees, BD remains dedicated to advancing the world of health. The company works closely with customers and partners globally to address complex health challenges, enhance clinical outcomes, and expand access to healthcare.
BD (Becton, Dickinson and Company) has updated the status of its voluntary recalls of the BD Alaris™ System, initiated on August 4, 2020. The FDA classified three recalls as Class I, indicating a significant risk of serious health consequences or death, while one was classified as Class II. The recalls address issues such as unresponsive keypad keys and incorrect module sizes for infusion pumps, potentially leading to delays or inaccuracies in medication delivery. Customers are advised to follow recall instructions provided by BD.
BD (Becton, Dickinson and Company) announced a study showing the BD Veritor™ System for Rapid Detection of SARS-CoV-2 is as effective as the Quidel Sofia 2 SARS Antigen Fluorescent Immunoassay. The research involved 361 patient samples, indicating a high agreement in testing accuracy. The BD Veritor™ Plus system showed better correlation with PCR results than its competitor. The study aims to assess performance in community settings and highlights the importance of various factors in understanding antigen assay performance. The findings support the rapid antigen tests' utility in managing COVID-19.
BD (Becton, Dickinson and Company) (NYSE:BDX) announced its participation in upcoming virtual investor healthcare conferences. The company will present at the Wells Fargo Securities 2020 Healthcare Conference on September 10, 2020, at 8:40 a.m. EDT, and the Morgan Stanley 18th Annual Global Healthcare Conference on September 16, 2020, at 8:45 a.m. EDT. Webcasts of these presentations will be available on their corporate website and can be replayed for seven days post-conference.
BD (Becton, Dickinson and Company) has updated its voluntary recall of the BD Alaris™ System due to hardware issues. The U.S. FDA has classified three of the situations as Class I recalls, indicating a high probability of serious health risks or death, while one situation is a Class II recall. The issues include damaged connectors and battery problems that may impact device operation. BD has provided corrective instructions to affected customers, emphasizing the importance of safety in medical technology.
BD (Becton, Dickinson and Company) announced the appointment of Kristen Stewart as the senior vice president of Strategy and Investor Relations, effective Aug. 31, 2020. Stewart brings nearly two decades of experience in the medical technology sector, having previously led research at Barclays Capital. Her role will focus on enhancing shareholder value and communicating BD's long-term growth strategy. Tom Polen, CEO of BD, expressed confidence in her strategic skills, while Christopher Reidy, CFO, noted her strong investment community ties.
BD (Becton, Dickinson and Company) will present at the UBS Genomics 2.0 and MedTech Innovations Virtual Summit on August 13, 2020, at 3:30 p.m. ET. A live webcast of the presentation will be available on the BD corporate website and can be replayed until August 20, 2020.
As a leading global medical technology company, BD focuses on improving health care delivery and diagnostics, enhancing safety, efficiency, and access worldwide.
BD (NYSE: BDX) announces a commitment of $7.8 million over three years to support the Helping Build Healthy Communities initiative, enhancing healthcare access for underserved populations. This funding will increase total investments to $22.6 million since 2013. The initiative, in collaboration with Direct Relief and NACHC, focuses on assisting community health centers, which serve nearly 30 million patients. The funds aim to boost innovative healthcare approaches, especially vital during the ongoing COVID-19 pandemic.
BD (Becton, Dickinson and Company) reported Q3 revenue of $3.855 billion, an 11.4% decrease year-over-year. Diluted EPS fell 35.8% to $0.97. Key segments showed mixed results: BD Medical revenue decreased 8.2%, BD Life Sciences dropped 10.1%, while BD Interventional saw a 20.3% decline. Despite challenges, BD noted strong demand for COVID-19 products and positive trends in healthcare procedures. Full-year revenue outlook is a 2.5% to 3.0% decrease, with adjusted EPS guidance between $9.80 and $10.00, reflecting a substantial decline from last year's figures.
BD (Becton, Dickinson and Company) announced a $24 million investment from the U.S. Department of Defense and Health and Human Services to enhance U.S. manufacturing of the BD Veritor™ Solution for SARS-CoV-2. This investment aims to boost production capacity by 50%, enabling the company to produce over 12 million test kits monthly by February 2021. The BD Veritor™ Plus assay's performance includes 84% sensitivity and 100% specificity, making it a critical tool for rapid COVID-19 diagnosis.
FAQ
What is the current stock price of Becton, Dickinson and Co. (BDX)?
What is the market cap of Becton, Dickinson and Co. (BDX)?
What does Becton, Dickinson and Company (BD) specialize in?
What are BD's main business segments?
What recent projects has BD undertaken?
How much of BD's revenue comes from international markets?
What significant acquisition has BD announced recently?
How many employees does BD have?
Where can I find more information about BD's financial performance?
What is the significance of the BD FACSDiscover™ S8 Cell Sorters?
Which regulatory body recently issued a safety communication regarding syringes?
What is BD's approach to sustainability?
